vapotherm develops and manufactures innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. over 1 million patients have been successfully treated with vapotherm hi-vni technology, and the number is growing rapidly every day. we have an unrelenting commitment to improving patient lives, significant sales growth, a dynamic and exciting work environment, and a focus on hiring and developing the very best people in the medical device industry. now is a great time to join our growing team. vapotherm is a privately held company located in exeter, new hampshire. for more information, visit www.vapotherm.com.
Company profile
Ticker
VAPO
Exchange
Website
CEO
Joseph Army
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
HGE Health Care Solutions, LLC • Vapotherm Access Care Management Network, LLC • Vapotherm Access Management Services, LLC • Vapotherm Holding Company, LLC ...
VAPO stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
1 Apr 24
S-8
Registration of securities for employees
27 Feb 24
8-K
Departure of Directors or Certain Officers
27 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Vapotherm Reports Fourth Quarter and Fiscal Year 2023 Financial Results
22 Feb 24
25-NSE
Exchange delisting
18 Dec 23
8-K
Vapotherm Announces Suspension of NYSE Listing
14 Dec 23
8-K
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock
11 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Vapotherm Reports Third Quarter 2023 Financial Results
8 Nov 23
Transcripts
VAPO
Earnings call transcript
2023 Q3
8 Nov 23
VAPO
Earnings call transcript
2023 Q2
8 Aug 23
VAPO
Earnings call transcript
2023 Q1
3 May 23
VAPO
Earnings call transcript
2022 Q4
23 Feb 23
VAPO
Earnings call transcript
2022 Q3
2 Nov 22
VAPO
Earnings call transcript
2022 Q2
7 Aug 22
VAPO
Earnings call transcript
2022 Q1
8 May 22
VAPO
Earnings call transcript
2021 Q4
26 Feb 22
VAPO
Earnings call transcript
2021 Q4
24 Feb 22
VAPO
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
4
Dorota McKay
29 Feb 24
4
BRIAN LAWRENCE
29 Feb 24
4
John Landry
29 Feb 24
4
Joseph Army
29 Feb 24
SC 13G/A
Kent Lake Capital LLC
16 Feb 24
SC 13G/A
Roystone Capital Management LP
14 Feb 24
SC 13G/A
Parian Global Management LP
14 Feb 24
SC 13G/A
Crow's Nest Holdings LP
14 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
8 Feb 24
4
ELIZABETH H WEATHERMAN
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.53 mm | 15.53 mm | 15.53 mm | 15.53 mm | 15.53 mm | 15.53 mm |
Cash burn (monthly) | 1.19 mm | 1.19 mm | 5.04 mm | 5.79 mm | 986.33 k | 2.60 mm |
Cash used (since last report) | 7.97 mm | 7.95 mm | 33.62 mm | 38.63 mm | 6.58 mm | 17.37 mm |
Cash remaining | 7.56 mm | 7.58 mm | -18.09 mm | -23.10 mm | 8.94 mm | -1.85 mm |
Runway (months of cash) | 6.3 | 6.4 | -3.6 | -4.0 | 9.1 | -0.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 1 |
Closed positions | 20 |
Increased positions | 0 |
Reduced positions | 26 |
13F shares | Current |
---|---|
Total value | 4.37 bn |
Total shares | 16.11 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Roystone Capital Management | 5.18 mm | $5.23 mm |
Vapotherm Investors | 1.96 mm | $54.98 mm |
Parian Global Management | 1.71 mm | $0.00 |
Integrated Core Strategies | 1.50 mm | $0.00 |
Hound Partners | 1.40 mm | $29.06 mm |
Gilde Healthcare Holding B.V. | 1.19 mm | $31.51 mm |
SightLine Partners | 833.39 k | $22.19 mm |
Flynn James E | 604.52 k | $16.24 mm |
Crow's Nest | 561.00 k | $1.42 bn |
Millennium Management | 345.77 k | $874.80 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Feb 24 | Brian Lawrence | Stock Option Common Stock | Grant | Acquire A | No | No | 0.915 | 6,834 | 6.25 k | 6,834 |
27 Feb 24 | Brian Lawrence | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 21.6 | 6,834 | 147.61 k | 0 |
27 Feb 24 | Brian Lawrence | Stock Option Common Stock | Grant | Acquire A | No | No | 0.915 | 6,625 | 6.06 k | 6,625 |
27 Feb 24 | Brian Lawrence | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 25.28 | 6,625 | 167.48 k | 0 |
27 Feb 24 | Brian Lawrence | Stock Option Common Stock | Grant | Acquire A | No | No | 0.915 | 3,550 | 3.25 k | 3,550 |
27 Feb 24 | Brian Lawrence | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 165.68 | 3,550 | 588.16 k | 0 |
27 Feb 24 | Joseph Army | Stock Option Common Stock | Grant | Acquire A | Yes | No | 0.915 | 24 | 21.96 | 24 |
27 Feb 24 | Joseph Army | Stock Option Common Stock | Sale back to company | Dispose D | Yes | No | 137.2 | 24 | 3.29 k | 0 |
27 Feb 24 | Joseph Army | Stock Option Common Stock | Grant | Acquire A | Yes | No | 0.915 | 6 | 5.49 | 6 |
27 Feb 24 | Joseph Army | Stock Option Common Stock | Sale back to company | Dispose D | Yes | No | 13.44 | 6 | 80.64 | 0 |
Press releases
Onymos and Vapotherm Announce Partnership to Create an End-to-End Internet of Medical Things Solution (IoMT)
20 Mar 24
Vapotherm to Unveil Access365 Home Ventilation Solution at MEDTRADE
15 Mar 24
Dr. David Yamane was awarded the Star Research Award at the 2024 Critical Care Congress for the presentation of the HYPERACT Study - a randomized controlled trial demonstrating Vapotherm's High Velocity Therapy effectively treats moderate-severe acute exacerbations of COPD, while improving patient comfort
6 Mar 24
Vapotherm's HVT 2.0 System Overcomes Regulatory Hurdles for Entry into South America's Largest Health Care Market
29 Feb 24